1. Home
  2. LUNG vs XWIN Comparison

LUNG vs XWIN Comparison

Compare LUNG & XWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LUNG
  • XWIN
  • Stock Information
  • Founded
  • LUNG 1995
  • XWIN 2003
  • Country
  • LUNG United States
  • XWIN United States
  • Employees
  • LUNG N/A
  • XWIN N/A
  • Industry
  • LUNG Industrial Specialties
  • XWIN Home Furnishings
  • Sector
  • LUNG Health Care
  • XWIN Consumer Discretionary
  • Exchange
  • LUNG Nasdaq
  • XWIN Nasdaq
  • Market Cap
  • LUNG 63.6M
  • XWIN 75.2M
  • IPO Year
  • LUNG 2020
  • XWIN N/A
  • Fundamental
  • Price
  • LUNG $1.41
  • XWIN $5.74
  • Analyst Decision
  • LUNG Buy
  • XWIN
  • Analyst Count
  • LUNG 7
  • XWIN 0
  • Target Price
  • LUNG $6.81
  • XWIN N/A
  • AVG Volume (30 Days)
  • LUNG 7.0M
  • XWIN 911.6K
  • Earning Date
  • LUNG 11-12-2025
  • XWIN 11-13-2025
  • Dividend Yield
  • LUNG N/A
  • XWIN N/A
  • EPS Growth
  • LUNG N/A
  • XWIN N/A
  • EPS
  • LUNG N/A
  • XWIN N/A
  • Revenue
  • LUNG $91,664,000.00
  • XWIN $16,959,274.00
  • Revenue This Year
  • LUNG $10.41
  • XWIN N/A
  • Revenue Next Year
  • LUNG $10.98
  • XWIN N/A
  • P/E Ratio
  • LUNG N/A
  • XWIN N/A
  • Revenue Growth
  • LUNG 15.59
  • XWIN 70.36
  • 52 Week Low
  • LUNG $1.35
  • XWIN $0.39
  • 52 Week High
  • LUNG $9.37
  • XWIN $6.08
  • Technical
  • Relative Strength Index (RSI)
  • LUNG 39.77
  • XWIN N/A
  • Support Level
  • LUNG $1.65
  • XWIN N/A
  • Resistance Level
  • LUNG $2.11
  • XWIN N/A
  • Average True Range (ATR)
  • LUNG 0.17
  • XWIN 0.00
  • MACD
  • LUNG -0.05
  • XWIN 0.00
  • Stochastic Oscillator
  • LUNG 7.24
  • XWIN 0.00

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: